Gossamer Bio (FRA:4GB) Total Liabilities : €271.19 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Total Liabilities?

Gossamer Bio's Total Liabilities for the quarter that ended in Jun. 2024 was €271.19 Mil.

Gossamer Bio's quarterly Total Liabilities declined from Dec. 2023 (€228.47 Mil) to Mar. 2024 (€214.03 Mil) but then increased from Mar. 2024 (€214.03 Mil) to Jun. 2024 (€271.19 Mil).

Gossamer Bio's annual Total Liabilities increased from Dec. 2021 (€196.64 Mil) to Dec. 2022 (€245.79 Mil) but then declined from Dec. 2022 (€245.79 Mil) to Dec. 2023 (€228.47 Mil).

Gossamer Bio Total Liabilities Historical Data

The historical data trend for Gossamer Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Total Liabilities Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

66.71

179.81

196.64

245.79

228.47

Gossamer Bio Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial															225.72	227.98	228.47	214.03	271.19

Gossamer Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gossamer Bio's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	47.315	+	(181.152	+	0.0010000000000048
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	228.47

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	286.027	-	57.559
	=	228.47

Gossamer Bio's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	41.977	+	(183.06	+	-2.1316282072803E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	46.156	+	0)
	=	271.19

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	346.933	-	75.74
	=	271.19

Gossamer Bio Total Liabilities Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GOSS:USA

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Headlines

No Headlines